Bank of New York Mellon’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$567K Sell
38,773
-994
-2% -$14.7K ﹤0.01% 3683
2026
Q1
$577K Sell
39,767
-738
-2% -$8.57K ﹤0.01% 3532
2025
Q4
$389K Sell
40,505
-9,585
-19% -$91.8K ﹤0.01% 3733
2025
Q3
$471K Buy
50,090
+3,059
+7% +$29.2K ﹤0.01% 3633
2025
Q2
$498K Sell
47,031
-1,323
-3% -$16.7K ﹤0.01% 3512
2025
Q1
$727K Sell
48,354
-2,175
-4% -$36.2K ﹤0.01% 3245
2024
Q4
$832K Buy
50,529
+8,711
+21% +$172K ﹤0.01% 3265
2024
Q3
$1.03M Sell
41,818
-19,662
-32% -$510K ﹤0.01% 3127
2024
Q2
$1.56M Buy
61,480
+10,439
+20% +$271K ﹤0.01% 2943
2024
Q1
$1.3M Sell
51,041
-4,438
-8% -$107K ﹤0.01% 3009
2023
Q4
$1.26M Sell
55,479
-5,619
-9% -$116K ﹤0.01% 3073
2023
Q3
$1.14M Sell
61,098
-77,984
-56% -$1.62M ﹤0.01% 3078
2023
Q2
$3.61M Sell
139,082
-5,738
-4% -$154K ﹤0.01% 2494
2023
Q1
$4.16M Sell
144,820
-2,001
-1% -$59.6K ﹤0.01% 2397
2022
Q4
$4.35M Sell
146,821
-3,660
-2% -$104K ﹤0.01% 2418
2022
Q3
$3.58M Buy
150,481
+12,531
+9% +$288K ﹤0.01% 2490
2022
Q2
$3.08M Buy
137,950
+4,847
+4% +$108K ﹤0.01% 2591
2022
Q1
$3.34M Buy
133,103
+844
+0.6% +$25.7K ﹤0.01% 2645
2021
Q4
$4.74M Sell
132,259
-7,127
-5% -$285K ﹤0.01% 2491
2021
Q3
$5.93M Sell
139,386
-3,366
-2% -$139K ﹤0.01% 2400
2021
Q2
$6.18M Sell
142,752
-15,057
-10% -$641K ﹤0.01% 2390
2021
Q1
$6.44M Sell
157,809
-1,388
-0.9% -$52.6K ﹤0.01% 2328
2020
Q4
$7.21M Sell
159,197
-6,403
-4% -$243K ﹤0.01% 2175
2020
Q3
$5.86M Sell
165,600
-38,902
-19% -$1.41M ﹤0.01% 2134
2020
Q2
$7.72M Sell
204,502
-4,627
-2% -$152K ﹤0.01% 1979
2020
Q1
$6.05M Sell
209,129
-14,802
-7% -$599K ﹤0.01% 1981
2019
Q4
$11.6M Sell
223,931
-11,095
-5% -$644K ﹤0.01% 1884
2019
Q3
$12.9M Sell
235,026
-20,476
-8% -$1.05M ﹤0.01% 1792
2019
Q2
$10.4M Sell
255,502
-3,236
-1% -$118K ﹤0.01% 1943
2019
Q1
$7.82M Buy
258,738
+244
+0.1% +$8.36K ﹤0.01% 2098
2018
Q4
$8.69M Sell
258,494
-26,271
-9% -$948K ﹤0.01% 1989
2018
Q3
$12M Sell
284,765
-217,938
-43% -$8.61M ﹤0.01% 1918
2018
Q2
$16.1M Sell
502,703
-23,666
-4% -$975K ﹤0.01% 1733
2018
Q1
$26.2M Sell
526,369
-1,017
-0.2% -$57.5K 0.01% 1400
2017
Q4
$28.4M Sell
527,386
-13,996
-3% -$775K 0.01% 1371
2017
Q3
$31.4M Buy
541,382
+50,949
+10% +$2.66M 0.01% 1284
2017
Q2
$24.2M Buy
490,433
+213,055
+77% +$9.81M 0.01% 1427
2017
Q1
$12M Buy
277,378
+19,457
+8% +$929K ﹤0.01% 1859
2016
Q4
$12.6M Buy
257,921
+53,922
+26% +$2.49M ﹤0.01% 1833
2016
Q3
$9.76M Sell
203,999
-1,097
-0.5% -$54.2K ﹤0.01% 1894
2016
Q2
$11M Sell
205,096
-29,988
-13% -$1.41M ﹤0.01% 1798
2016
Q1
$10.5M Sell
235,084
-7,962
-3% -$323K ﹤0.01% 1811
2015
Q4
$9.28M Sell
243,046
-40,211
-14% -$1.54M ﹤0.01% 1880
2015
Q3
$9.02M Buy
283,257
+7,332
+3% +$256K ﹤0.01% 1920
2015
Q2
$9.11M Buy
275,925
+8,829
+3% +$315K ﹤0.01% 2012
2015
Q1
$11M Buy
267,096
+22,429
+9% +$907K ﹤0.01% 1896
2014
Q4
$9.97M Buy
244,667
+8,809
+4% +$344K ﹤0.01% 1916
2014
Q3
$8.65M Buy
235,858
+29,492
+14% +$1.27M ﹤0.01% 1990
2014
Q2
$9.56M Buy
206,366
+28,163
+16% +$1.25M ﹤0.01% 1951
2014
Q1
$7.33M Buy
178,203
+39,024
+28% +$1.45M ﹤0.01% 2096
2013
Q4
$5.31M Buy
139,179
+52,199
+60% +$1.61M ﹤0.01% 2262
2013
Q3
$2.08M Buy
86,980
+274
+0.3% +$6.15K ﹤0.01% 2833
2013
Q2
$1.47M Buy
+86,706
New +$1.25M ﹤0.01% 2956

Other funds holding ANIK

Bank of New York Mellon's ANIK Position: Q2 2026 in Review

Bank of New York Mellon reduced its Anika Therapeutics (ANIK) stake by 2.5% in Q2 2026, selling an estimated $14.7K and leaving 38,773 shares worth $567K. The position accounts for ﹤0.01% of the portfolio, ranked #3683.

Bank of New York Mellon first reported a position in ANIK in Q2 2013 and has held it in 53 quarters since. The position peaked at $31.4M in Q3 2017. 68 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Bank of New York Mellon held 38,773 shares of Anika Therapeutics worth $567K as of Q2 2026.
  • Bank of New York Mellon sold 994 Anika Therapeutics shares in Q2 2026, an estimated $14.7K.
  • Anika Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3683 holding.
  • Bank of New York Mellon first reported a position in Anika Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Bank of New York Mellon's Anika Therapeutics position peaked at $31.4M in Q3 2017.
  • 68 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.